Viromed Medical AG (Q11) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viromed Medical AG (Q11) has a cash flow conversion efficiency ratio of -0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.12 Million ≈ $-11.83 Million USD) by net assets (€269.20 Million ≈ $314.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Viromed Medical AG - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Viromed Medical AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Viromed Medical AG carry for a breakdown of total debt and financial obligations.
Viromed Medical AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viromed Medical AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Continental Holdings Corp
TW:3703
|
0.024x |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
0.036x |
|
SHANDONG BOAN BIOTECH.H 1
F:UJ9
|
N/A |
|
Mahindra Holidays & Resorts India Limited
NSE:MHRIL
|
0.349x |
|
Nanjing Well Pharmaceutical Co Ltd
SHG:603351
|
0.039x |
|
IS Dongseo
KO:010780
|
0.003x |
|
Neosem Inc
KQ:253590
|
0.003x |
|
Hunan Chen Dian International Development Co Ltd
SHG:600969
|
0.109x |
Annual Cash Flow Conversion Efficiency for Viromed Medical AG (2021–2024)
The table below shows the annual cash flow conversion efficiency of Viromed Medical AG from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Viromed Medical AG stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €201.16 Million ≈ $235.17 Million |
€-6.03 Million ≈ $-7.04 Million |
-0.030x | +94.36% |
| 2023-12-31 | €64.28 Million ≈ $75.15 Million |
€-34.16 Million ≈ $-39.93 Million |
-0.531x | -60.96% |
| 2022-12-31 | €63.23 Million ≈ $73.92 Million |
€-20.87 Million ≈ $-24.40 Million |
-0.330x | +40.80% |
| 2021-12-31 | €39.97 Million ≈ $46.73 Million |
€-22.29 Million ≈ $-26.06 Million |
-0.558x | -- |
About Viromed Medical AG
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.